Testing a new drug for diabetic eye disease after vitrectomy
Part of Eyes & vision clinical trials.
This trial tests a new medicine, RRG001, given after vitrectomy surgery for severe diabetic eye disease. It aims to see if the drug is safe and helps prevent vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 20 years old or older
- You have diabetes (type 1 or type 2)
- You have severe diabetic eye disease that needs or has had vitrectomy surgery
- Your vision in the study eye is at least hand motion but no better than 20/40 (about 63 letters on an eye chart)
- You have not had gene therapy or major eye surgery (other than for your diabetic eye disease) in either eye
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how people with severe nonproliferative diabetic retinopathy do after they have vitrectomy (a type of eye surgery). The goal is to better predict prognosis and possibly improve care planning after surgery.
This trial compares two treatments for early diabetic retinopathy—a condition where high blood sugar damages blood vessels in the eye. Researchers want to see if removing fluid from inside the eye (vitrectomy) works better than laser treatment to prevent vision loss.
This trial tests an injection called PUMCH-E101 for people with vision loss caused by changes in the RDH12 gene. The goal is to see if it is safe and if it can help improve vision.
This trial tests whether giving bevacizumab (a medicine that slows abnormal blood vessel growth) right after vitrectomy (a surgery to remove blood or scar tissue from the eye) can help people with advanced diabetic eye disease. The goal is to improve vision and reduce the need for more treatments.
This trial tests a different pattern of laser treatment for people with diabetic eye disease (proliferative diabetic retinopathy) that has started growing abnormal blood vessels. The goal is to see if this pattern works well or better than the standard approach.
This is an early-stage safety study testing a new medicine injected directly into the eye to treat diabetic retinopathy (damage to blood vessels in the retina caused by diabetes). The study checks if the medicine is safe and how the body processes it.
Hear when a new PDR - Proliferative Diabetic Retinopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.